Sanofi India Limited (SANOFI) AI Stock Analysis

• Market Cap: ₹106.88B
• Dividend Yield: 4.14%
• Average Volume (3M): 3.53K
• Price to Earnings (P/E): 30.0
• Beta (1Y): 0.82
• Revenue Growth: -19.94%
• EPS Growth: -22.49%
• Country: IN
• Employees: 1,225
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 41.80
• Shares Outstanding: 23,030,000
• 10 Day Avg. Volume: 3,027
• 30 Day Avg. Volume: 3,526
• PEG Ratio: -2.44
• Price to Book (P/B): 16.38
• Price to Sales (P/S): 7.00
• P/FCF Ratio: 33.17
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: ₹5,188.00 ▲(10.97% Upside)

Sanofi India Limited's strong financial performance is the most significant factor, supported by a solid balance sheet and efficient cash flow management. However, technical indicators suggest bearish momentum, which could pose short-term challenges. The valuation is reasonable, with a fair P/E ratio and a decent dividend yield, providing some support to the stock's attractiveness.

Sanofi India Limited Business Overview & Revenue Model

Company Description

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singaporem and internationally. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous system, anti-infective, epilepsy, allergy and vitamins, anti-histamines, and minerals and supplements under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. The company also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

How the Company Makes Money

Sanofi India Limited generates revenue through multiple streams, primarily from the sale of prescription medicines and vaccines. The company markets a diverse portfolio of pharmaceutical products, which accounts for a significant portion of its earnings. Sanofi also engages in consumer healthcare, offering over-the-counter products that contribute to its revenue. Key revenue streams include sales from its diabetes care segment, particularly insulin, as well as other therapeutic areas such as cardiovascular health and oncology. Strategic partnerships with healthcare providers and institutions enhance its market reach and support its revenue generation. Additionally, the company may benefit from collaborations in research and development, enabling it to innovate and expand its product offerings, contributing further to its financial performance.

Sanofi India Limited Financial Statement Overview

Summary

Sanofi India Limited demonstrates a robust financial position with strong profitability and efficient cash flow management. Despite some volatility in revenue and profit margins, the company's low debt levels and substantial equity offer a cushion against financial instability.

Income Statement

Sanofi India Limited shows a consistent gross profit margin, indicating a stable cost structure. However, the net profit margin has declined from 2023 to 2024, highlighting some challenges in controlling non-operational costs. Revenue growth has been inconsistent, with a notable decrease in 2024 compared to previous years. EBIT and EBITDA margins have also seen fluctuations, reflecting volatility in operational efficiency.

Balance Sheet

The company maintains a very healthy debt-to-equity ratio, demonstrating strong financial leverage management. The equity ratio remains robust, indicating a solid equity base relative to total assets. However, there is a slight decrease in stockholders' equity in 2024, which may warrant monitoring. Overall, the balance sheet reflects financial stability and low risk of over-leverage.

Cash Flow

Sanofi India Limited exhibits strong free cash flow, with an impressive free cash flow to net income ratio, suggesting efficient cash generation relative to earnings. The operating cash flow to net income ratio is solid, indicating good cash earnings quality. While free cash flow growth has been positive, it has shown variability in recent years, requiring attention to sustaining cash flow momentum.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	19.16B	20.13B	19.96B	27.70B	29.57B	29.02B
Gross Profit	9.58B	10.19B	10.31B	15.65B	16.33B	16.23B
EBITDA	4.63B	4.85B	4.85B	6.98B	7.54B	7.09B
Net Income	3.38B	4.13B	6.03B	6.21B	9.44B	4.78B
Balance Sheet
Total Assets	12.39B	16.12B	17.15B	20.72B	30.61B	29.18B
Cash, Cash Equivalents and Short-Term Investments	3.13B	3.40B	3.94B	10.05B	15.38B	11.97B
Total Debt	209.00M	193.00M	190.00M	236.00M	246.00M	226.00M
Total Liabilities	4.57B	7.51B	7.00B	7.96B	8.35B	8.00B
Stockholders Equity	7.82B	8.61B	10.15B	12.76B	22.26B	21.19B
Cash Flow
Free Cash Flow	2.77B	4.25B	1.96B	3.77B	5.36B	5.70B
Operating Cash Flow	2.91B	4.62B	2.30B	3.99B	5.59B	6.11B
Investing Cash Flow	-71.00M	-192.00M	375.00M	6.51B	6.31B	2.76B
Financing Cash Flow	-2.73B	-3.92B	-8.78B	-15.83B	-8.49B	-8.10B

Sanofi India Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4675.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SANOFI, the sentiment is Negative. The current price of 4675.05 is above the 20-day moving average (MA) of 4653.62, below the 50-day MA of 4797.13, and below the 200-day MA of 5428.53, indicating a bearish trend. The MACD of -32.78 indicates Negative momentum. The RSI at 41.52 is Neutral, neither overbought nor oversold. The STOCH value of 1.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SANOFI.

Sanofi India Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DRREDDY	73 Outperform	₹1.00T	17.09	―	0.66%	14.10%	9.72%
CIPLA	68 Neutral	₹1.21T	22.32	―	0.86%	6.93%	21.55%
SANOFI	67 Neutral	₹106.88B	30.00	―	4.14%	-19.94%	-22.49%
ABBOTINDIA	67 Neutral	₹624.01B	42.97	―	1.65%	10.69%	17.46%
GLAXO	63 Neutral	₹450.87B	47.45	―	2.08%	4.17%	41.51%
GLENMARK	53 Neutral	₹521.13B	69.14	―	0.14%	10.99%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Sanofi India Limited Corporate Events

Sanofi India Announces Key Leadership Changes

Sanofi India Limited announced a change in its board of directors, appointing Mr. Deepak Arora as an Additional Director and Managing Director for a three-year term starting October 27, 2025. This appointment follows the stepping down of Mr. Rachid Ayari from his role as Interim Managing Director, though he will continue as Whole-time Director and Chief Financial Officer. These changes are expected to impact the company’s leadership dynamics and strategic direction.

Sanofi India Announces Leadership Changes with New Managing Director Appointment

Sanofi India Limited announced the cessation of Mr. Rachid Ayari as the Interim Managing Director effective October 26, 2025. Mr. Ayari will continue as the Whole-time Director and Chief Financial Officer. The Board has appointed Mr. Deepak Arora as an Additional Director and Managing Director for a three-year term starting October 27, 2025. This leadership change is expected to impact the company’s strategic direction and operational management, with Mr. Arora authorized to determine and disclose material events to stock exchanges.

Sanofi India Appoints New Managing Director

Sanofi India Limited has announced the appointment of Mr. Deepak Arora as the new Managing Director, effective October 27, 2025, for a three-year term. This decision follows the recommendation of the Nomination and Remuneration Committee and awaits approval from shareholders and the Central Government. Mr. Arora will also have the authority to disclose material events to stock exchanges. The appointment marks a strategic leadership change as Mr. Rachid Ayari steps down from his interim role but continues as the Chief Financial Officer and Whole-time Director. This transition is expected to strengthen Sanofi India’s management team and enhance its operational effectiveness.

Sanofi India Schedules Investor Call to Discuss Financial Results

Sanofi India Limited has announced an investor and analysts call scheduled for October 29, 2025, to discuss its unaudited financial results for the quarter and nine months ending September 30, 2025. This call will provide stakeholders with insights into the company’s financial performance and strategic direction, potentially impacting investor confidence and market positioning.

Sanofi India Announces Key Management Change

Sanofi India Limited has announced a key change in its management team, with Mr. Arjun Thakkar resigning as the Company Secretary and Compliance Officer, effective 30th September 2025, to take on another role within the Sanofi group. Mr. Haresh Vala has been appointed as his successor, effective 1st October 2025, and will also serve as a Key Managerial Personnel and Senior Management Personnel. This transition is significant for the company as it continues to align its leadership structure with its strategic objectives, ensuring compliance and effective communication with stock exchanges.

Sanofi India Launches ‘Saksham Niveshak’ Campaign to Engage Shareholders

Sanofi India Limited has announced a 100-day campaign titled ‘Saksham Niveshak’ from July 28, 2025, to November 6, 2025, aimed at facilitating dividend claims, updating KYC details, and preventing the transfer of unpaid or unclaimed dividends to the Investor Education and Protection Fund Authority. This initiative is part of a broader effort to engage shareholders and ensure they receive their due dividends while maintaining updated records, which could enhance shareholder satisfaction and operational transparency.

Sanofi India Reports Growth in Operating Profit Amid Sales Decline

Sanofi India Limited reported a 2% decline in net sales year-to-date but achieved a 6% growth in profit from operations for the period ending June 2025. The company attributes this growth to cost optimization and operational efficiencies. Despite a 9% decline in net sales on a comparable basis, Sanofi India saw strong performance in its diabetes portfolio with the successful launch of Soliqua® and continued growth of Toujeo®. Strategic partnerships in the CV and CNS segments have expanded market reach, although export sales were impacted by the discontinuation of the Zentiva portfolio. The company remains focused on operational excellence and innovation to drive its India strategy.

Sanofi India Limited Announces Financial Results and Leadership Changes

Sanofi India Limited announced the approval of its unaudited financial statements for the quarter and half-year ended June 30, 2025, reflecting compliance with SEBI regulations. The company also disclosed significant management changes, with the retirement of Ms. Renee Amonkar as Whole-time Director and Site Director – Goa, effective August 11, 2025, and the appointment of Mr. Mahadev Gawade as her successor. These changes are expected to impact the company’s leadership dynamics and strategic direction.